Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2025, MARKER THERAPEUTICS, INC. reported revenue of $4M, down 46.2% year over year. Operating margin was -363.5% and net margin -343.0%, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from MRKR's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $4M | -363.5% | -343.0% |
| FY2024 | $7M | -168.7% | -162.8% |
| FY2023 | $3M | -440.4% | -248.8% |
| FY2022 | $4M | -563.3% | -851.9% |
| FY2021 | $0M | n/a | n/a |
How does MRKR compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.